Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study.
8049 Background: The National LymphoCare Study (NLCS) collects data on disease
presentation, treatment patterns, and clinical outcomes for 2736 patients with with follicular …
presentation, treatment patterns, and clinical outcomes for 2736 patients with with follicular …
[HTML][HTML] Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: a long-term survey on 597 patients
C Tarella, A Gueli, F Delaini, AM Barbui, R Bruna… - Blood, 2015 - Elsevier
BACKGROUND Follicular lymphoma (FL) is the most common indolent form of non-
Hodgkin's lymphoma. However, FL is a heterogeneous disorder and in a proportion of …
Hodgkin's lymphoma. However, FL is a heterogeneous disorder and in a proportion of …
Bendamustine plus Rituximab versus R‐CHOP as first‐line treatment for patients with Follicular Lymphoma grade 3A: evidence from a multicenter, retrospective study
P Mondello, N Steiner, W Willenbacher… - The …, 2018 - academic.oup.com
Background Rituximab plus bendamustine (R‐B) has been demonstrated to improve
outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and …
outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and …
Fludarabine, cyclophosphamide and rituximab as first‐line treatment in patients with newly diagnosed follicular lymphoma
F De la Cruz Vicente, E Carrillo‐Cruz… - European Journal of …, 2014 - Wiley Online Library
Fludarabine‐based regimens are highly effective as first‐line therapy in patients with
follicular lymphoma. Nevertheless, noticeable haematological toxicity has been reported …
follicular lymphoma. Nevertheless, noticeable haematological toxicity has been reported …
Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era
REI Prusila, M Sorigue, J Jauhiainen… - British journal of …, 2019 - Wiley Online Library
Follicular lymphoma (FL) is the most common indolent lymphoma. Currently there are many
comparable treatment options available for FL. When selecting the most optimal therapy it is …
comparable treatment options available for FL. When selecting the most optimal therapy it is …
[HTML][HTML] Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the …
R Bruna, F Benedetti, C Boccomini, C Patti… - …, 2019 - ncbi.nlm.nih.gov
A prospective trial conducted in the period 2000-2005 showed no survival advantage for
high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional …
high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional …
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated …
F Morschhauser, L Nastoupil, P Feugier… - Journal of Clinical …, 2022 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …
report, typically based on the primary end point, may be published when key planned co …
[HTML][HTML] Outcomes of follicular lymphoma patients treated with frontline bendamustine and rituximab: impact of histologic grade and early progression on overall …
AM Winter, LJ Nastoupil, MR Becnel, JR Cerhan… - Blood, 2018 - Elsevier
Background: Bendamustine and rituximab (BR) is a commonly chosen frontline treatment for
grade 1-2 (G 1-2) follicular lymphoma (FL). This regimen resulted in significantly longer …
grade 1-2 (G 1-2) follicular lymphoma (FL). This regimen resulted in significantly longer …
Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern …
E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma
JD Hainsworth, FA Greco, EL Raefsky… - … Myeloma and Leukemia, 2014 - Elsevier
Abstract Introduction/Background Inhibition of tumor angiogenesis by the interruption of
VEGF pathway signaling is of therapeutic value in several solid tumors. Preclinical evidence …
VEGF pathway signaling is of therapeutic value in several solid tumors. Preclinical evidence …